PUBLISHER: Grand View Research | PRODUCT CODE: 1363236
PUBLISHER: Grand View Research | PRODUCT CODE: 1363236
The global male urinary incontinence market size is anticipated to reach USD 10.02 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 5.87% from 2023 to 2030. Rapid advancements in technology, an increasing demand for minimally invasive procedures, rising healthcare expenditure, and advancements in non-absorbent & absorbent products drive industry growth. Also, the increasing prevalence of chronic diseases is anticipated to expand the market for male urinary incontinence globally.
One of the key factors driving market expansion is the rapid technical advancements linked to incontinence. Synthetic MS for Proton Pump Inhibitors (PPI) has risen in popularity in recent years since it is less expensive, less intrusive, and does not require mechanical manipulation during voiding. For example, the innovation of fit and efficient pouching systems and associated accessories to improve patient's quality of life is projected to drive the market.
Boston Scientific Corporation, Coloplast Corp., and Teleflex Incorporated are a few of the key players in the market that are investing significantly in research and development activities to introduce new products. For instance, Coloplast Corp. launched its innovative male catheter Luja in February 2023, making it the first and only male catheter with over 80 micro-holes designed to address the primary urinary tract infection risk factor linked with intermittent catheterization.
Despite its potential for expansion, the male urinary incontinence industry faces obstacles such as a lack of knowledge and inconsistent reimbursement rules. Technological developments, better patient education, and continuous research, on the other hand, are projected to stimulate the development of more effective and less intrusive treatment alternatives. Furthermore, the combination of digital health solutions and telemedicine may help improve access to diagnosis and treatment for males with urine incontinence.